A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Inclusion Criteria: * Age 6 months to \<12 years at screening. * Body weight ≥9 kg at screening. * Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD. * History of AD for: ≥12 months for subjects aged ≥6 years at screening and ≥3 months for subjects aged 6 months to \<6 years at screening. * Documented inadequate response to mid-strength TCS within 6 months before the screening visit. * AD involvement of ≥10% body surface area at screening and baseline according to component A of SCORAD. * An EASI score of ≥16 at screening and baseline. * An IGA score of ≥3 at screening and baseline. * A Child Worst Itch NRS average score of ≥4 (subjects aged ≥6 years at screening) or a Scratch ObsRO average score of ≥4 (subjects aged \<6 years at screening) during the week prior to baseline. Exclusion Criteria: * Treatment with the topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), topical phosphodiesterase-4 inhibitors (PDE-4), and topical Janus kinase inhibitors (JAK) within 1 week prior to baseline. * Treatment with bleach baths within 1 week prior to baseline. * Treatment with the immunomodulatory medications systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors) and systemic corticosteroids (excludes inhaled, ophthalmic, or intranasal delivery) within 4 weeks prior to baseline. * Use of tanning beds or phototherapy within 4 weeks prior to baseline. * Treatment with a live (attenuated) or non-live vaccine within 30 days prior to the baseline visit. * Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment such as seborrheic dermatitis, active skin infection, scabies, cutaneous T cell lymphoma, or psoriasis. * Clinically significant active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals or antiprotozoal within 2 weeks before the baseline visit. * History of past or current hepatitis B or C including a positive hepatitis B or C test at screening.